Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
MTR Investors Group goal is to provide the best Covered / Naked, Credit Spread, and Iron Condor Option Screeer on the web. Screen over 3,100 stocks and over 270,000 options in seconds to find the best possible trades!
Option writers use our screener to find options trades that have the highest probability of expiring worthless.
Attempting to find profitable option trades on over 3,100 stocks and over 250,000 options, and millions of Credit Spread and Iron Condor combinations is a huge effort. The MTR option screener simplifies that process and will discover trades that otherwise would be missed.
This is an end of day screening service. It is geared toward traders that look for trading opportunities after hours to prepare for the next trading day.
We use Stock Market Scout (SMS) as a model to indicate allocating cash to an index ETF (such as SPY) by going long on Green, cash on Yellow, short on Red (or stay in cash). This is not a recommendation to buy or sell SPY.
We are proud to offer powerful tools for free or at price point that allows any investor to have an edge.
36 year old part time investor and trader. I concentrate on finding inefficiencies in the market resulting from behavioral biases that distort the decision making of individual and institutional investors. I still consider myself to be a novice trader, as my experience spans a over a decade. I've beaten the market substantially over most of those years, but the mistakes I've made in that time have been rather expensive. I'm hoping that I can keep my mind open and learn from reading various viewpoints.
I’m an Army engineer in the electrical field, working in the power generation/transmission industry. Also, I'm a graduate student pursuing my MBA. I have a BS in Management and have developed an avid interest in world economics and finance. I consider myself a recreational investor – a sort of "everyman" investor looking to increase my knowledge of the investment community and principles while making some money at the same time. I try to write articles from this frame of mind. I tend to look for undervalued and under-covered companies and enjoy doing a thorough fundamental analysis before making an investment decision, and looking for at least 2-3 technical indicators to time a purchase.
I encourage all to do their own research and due diligence prior to making any investment decision. It is a necessary skill one must constantly be perfecting in order to be successful. If you do like my articles, please follow me. And if you do decide to invest in any company I write about, please feel free to message me in the future to let me know how it turned out. I love communicating and interacting with other investors of similar styles.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
10 years investing in $10 or less stocks. My portfolio has grown from an initial $4K investment to well over a million in that period of time. I specialize in identifying under-the-radar, unloved stocks with great upside.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
I am a Business Administration graduate from the University of Central Florida and was a law student at Nova Southeastern University. I follow both the technology segment and the area of Intellectual Property.
Andreas Schreyer, Founder and Editor of The Green Investor and the Investoblog, is a longtime investor and student of the markets and has been a financial newsletter editor since 2003. He continues as a partner at Fraser Partners and at MarketTrend Advisors, a full service investment advisory firm.
In addition to his investment background, Andreas has over 30 years of experience in the high tech industry, including electronics, computer and software. His career began in engineering (he has a degree in Electrical Engineering from Ecole Technique Superieure, Geneva, Switzerland). After some years in design engineering he moved to the product management and strategic planning disciplines, with positions of increasing responsibility for Fortune 500 corporations such as Motorola and Tandem Computers (later part of Compaq and now of Hewlett Packard). Andreas also served in executive management positions at a number of start-up companies such as Internet Dynamics and Globeset before moving to the financial investment newsletter sector.
I am an active investor in IP-centric investments for 5 years. I specialize in high risk / high reward situations both public and private. It is important for investors to plan for all outcomes as the litigation surrounding the IP investment takes many twists and turns. Extracting profits and limiting exposure are the keys to success.
I hope to provide information and strategies, which both expert and novice IP investors can profit from.
Follow me on twitter for the latest updates in the IP space:
With a couple of decades of experience as an option market maker and institutional floor broker on the trading floor, I have some opinions (not always right). I do have a decent grasp of options and market mechanics. I have lectured and consulted for exchanges, the SEC, universities, and private investment funds as well as taught courses in the financial field.
Working for a financial software company takes a good part of my time (Silexx Financial Systems, a financial software company that designed the trading/risk management platform, Obsidian, is a vendor-neutral stock, equity and option trading platform.)
The bulk of my time is managing partner of Kinetic Investment Group - a private investment firm. We have a great team of guys/gals and the products we are working on are exciting. www.kineticgrp.com
Of course there is a DAILY news letter I type up every morning before the sun comes up and email out.
Being neither a Democrat or Republican – I fall somewhere in the Austrian / Chicago School of Thought, some would even say more laissez faire. One of my favorite American historical figures is Thomas Paine. I like to believe that I try to measure up to Paine's quote: "The most formidable weapon against errors of every kind is Reason. I have never used any other, and I trust I never shall."
Moon Kil Woong is currently a VP at a SME. Previously he was a tech stock consultant, VP of Research at ING, and sell side Director at Crédit Agricole Indosuez. Moon Kil Woong has a Masters in Public Administration from SJSU.
Investing forever. Ok not forever but I have been doing my own trading since age 19 when I used to get charged like 200 bucks each way. Full commission sucked!. I have had a good bit of success. I have also had enough failure to make me realize that success in the past is not guaranteed by any long shot and no indicator of future success by any means.
I have been in technology since I was nine. I have been working in the field officially since I was 18.
I mix fundamentals and technicals but like most of you my gut and intuition still play an important role in trading because to ignore that aspect is to think the herd does not matter and in many cases the herd matters more than either technical or fundamental aspects of a stock.
I have been an investor in several stock exchanges around the globe for the last 16 years. My trading philosophy is to be ahead of the curve of demand. I strongly believe that diligence and patience are fundamental to stock market success.
I attained my MBA from the Keio Business School and have worked in the field of international business consulting for the last 12 years. My job has allowed me to travel the world, which gives me great joy, as it combines my two passions, to visit new places and finance.
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation.
We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters.
Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case.
Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.
I focus on analyzing micro and small-cap companies that appear to poised for outsized gains compared to the market. I reach my investing decisions based upon fundamental, technical, and macro indicators. I have previously worked as a volatility trader and long/short equity analyst.
I work in the medical and healthcare field so my focus is mainly on Biotech stocks. I try to find the next Celgene, the next Pharamcylics if possible.
Been a trader and investor for 13 years.
Love the game, and I hope you enjoy my articles on here.
Good luck with your investments and I look forward to all of your comments and suggestions.
Read more here
I have been a professional writer for over 20 years. I also have enjoyed searching micro and nano cap companies looking for hidden gems. Having grown up around stock brokers and commodities traders I have seen the business from both sides. I have been an investor in the market for most of my life.
Electrical Engineer and private investor. I reside in the heart of Miyazaki, Nippon (Japan) about half time, and in my 727 home in Oregon, America, the other half (AirplaneHome.com, HikoukiIe.com, and AirplaneHome.com/Images/CoyMediaPagesCatalog.html). I'm 66 years of age (as of 2016).
I seem to be chronically incapable of conveying concepts concisely. For those who suffer through my rambling, redundant, and serpentine rhetoric, my sincere apologies. I do perceive that my composition desperately needs to be more efficient, so I'll try to make it so.
I'm also incompetent in most facets of the technology areas I invest in. I'm a good circuit design engineer, but I know precious little about integrated circuit fabrication technology and many other specialities. So I depend upon others, mostly here on Seeking Alpha, who have direct experience in areas where I have little or none. The bread which appears on my table (and the jetliner which resides in my yard) arrived largely on the shoulders of those who contribute here and others from past times, and I'm genuinely grateful for their energetic and community minded generosity.
In an effort to improve perspective, I try to keep two key long term cyber system goals in mind as I try to judge whether a firm possesses a clear vision of the future. The first is the Smoking Hairy Golf Ball, an idealized liquid helium cooled semiconductor sphere with wire connections on its surface, envisioned long ago as the final stage of evolution for maximum performance solid state electronics systems. The second, and most important, is a HAL-9000 algorithm, that is, conscious life creating software. Setting aside considerations of whether it's wise to pursue that second goal, firms which steer themselves toward either or both of these goals, in the context of developing their more ordinary products, are, in my view, likely to be lucrative. And for the record, I suspect a HAL-9000 algorithm will prove to be wonderfully positive for humanity. If we develop and manage the technology wisely and compassionately...
In my view some firms are moving, step by tiny step, toward one or both of these milestones.
I'm eager to hear constructive and civil criticism, so please don't hesitate to offer your suggestions.
Itsu made mo, genki de ite kudasai (Be healthy and, by implication, happy forever please), Bruce
Electrical-engineer-turned-patent-and-mortgage-backed-securities-litigator-turned-amateur-trader. If you've ever spoken to an engineer or a lawyer for more than a few minutes, then you understand what inspired the shifts.
EXP is a graduate from The University of Wall Street and serves as the CEO / Chief Stock Strategist at EXPstocktrader.com research firm.
With over 30 years of trading the market, EXP is an experienced investor using a fundamental and technical approach as a market analyst, chartist, visual analyst, as well as, a trader, author, coach, and serial entrepreneur. Extremely dedicated by investing countless hours investigating, analyzing, then writing about unique stock opportunities, as well as, coaching existing followers worldwide. EXP delivers "Real Facts" to Seeking Alpha and Twitter followers on monthly stock selections. Not all of the research found in the EXPstocktrader Monthly Newsletter is openly published online so EXP's members get updates first. Note: Most stocks covered have a unique niche or value proposition.
The Goal is to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. From the EXPstocktrader.com website you will find an offering for a newsletter that gives interested followers several trading ideas and stock lessons on a monthly basis. SA followers only see a very small part of EXP's published research.
This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them.
EXP resides in the USA, and is thankful to followers worldwide.
You can also follow EXPstocktrader on:
Twitter --- @EXPstocktrader
Website --- http://www.EXPstocktrader.com
Email --- firstname.lastname@example.org
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader.com and SA are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Patent News. We publish all the latest insights about patents and patent cases and ways to make profits from trading/investing in these up and coming companies.
Feel free to contact with any questions.
We await your reply.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
John Kozey is Director of Research at KnowVera, LLC, where he oversees research and trading of algorithmic trading strategies. Prior to that, as a Senior Analyst at Thomson Reuters, he produced reports blending fundamental and technical analysis for actionable ideas. John was also Equity Research Director for Bridge Trading Company, as well as a former institutional equity derivatives salesman, sales-trader and desk strategist/analyst. He holds the Chartered Financial Analyst (CFA) , Chartered Market Technician (CMT) and Accredited Wealth Management Advisor (AWMA) designations. He received his MBA in Finance from Cornell’s Johnson School of Management.